Wellington Management Group LLP Purchases Shares of 107,820 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Wellington Management Group LLP bought a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 107,820 shares of the biotechnology company's stock, valued at approximately $819,000. Wellington Management Group LLP owned approximately 0.05% of BioCryst Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. CWM LLC grew its holdings in shares of BioCryst Pharmaceuticals by 200.0% in the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 3,772 shares during the period. Signaturefd LLC grew its holdings in BioCryst Pharmaceuticals by 560.5% in the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 5,599 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock valued at $57,000 after buying an additional 1,322 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter worth $63,000. Finally, Quantinno Capital Management LP purchased a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter worth about $82,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Price Performance

BCRX stock traded up $0.18 during midday trading on Friday, hitting $7.57. The stock had a trading volume of 5,070,691 shares, compared to its average volume of 2,851,450. The company's 50-day moving average price is $7.62 and its 200 day moving average price is $7.42. The firm has a market cap of $1.57 billion, a PE ratio of -12.41 and a beta of 1.79. BioCryst Pharmaceuticals, Inc. has a 12-month low of $4.03 and a 12-month high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). The business had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. BioCryst Pharmaceuticals's revenue for the quarter was up 35.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.19) EPS. As a group, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Barclays lifted their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a research report on Tuesday, November 5th. Needham & Company LLC reaffirmed a "buy" rating and issued a $14.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, BioCryst Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $15.60.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.